Sandoz Group AG (SDZNY)
OTCMKTS
· Delayed Price · Currency is USD
44.97
+0.11 (0.25%)
May 13, 2025, 11:12 AM EDT
Sandoz Group AG Revenue
In the year 2024, Sandoz Group AG had annual revenue of $10.38B with 4.06% growth. Sandoz Group AG had revenue of $5.32B in the half year ending December 31, 2024, with 14.92% growth.
Revenue
10.38B
Revenue Growth
+4.06%
P/S Ratio
1.86
Revenue / Employee
470.95K
Employees
22,049
Market Cap
19.33B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Sandoz Group AG News
- 10 days ago - Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed - GlobeNewsWire
- 14 days ago - Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar - Seeking Alpha
- 14 days ago - Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications - GlobeNewsWire
- 15 days ago - Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access - Reuters
- 4 weeks ago - Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG - GlobeNewsWire
- 4 weeks ago - Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug - Benzinga
- 4 weeks ago - [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - GlobeNewsWire